Table 3.
Proteins identified as more abundant in cancer (malignant strictures) than in controls (primary sclerosing cholangitis and benign strictures)
| Proteins | Accession | MW (kDa) | Average SC |
NSAF ratio | P-value (t-test) | |
|---|---|---|---|---|---|---|
| Cancer | Control | |||||
| Fibrinogen beta chain isoform 1 pre-pro-protein | 70906435 | 56 | 138.8 | 52.1 | 2.2 | 0.01481 |
| C4b-binding protein alpha chain precursor | 4502503 | 67 | 37.3 | 11.5 | 2.3 | 0.04311 |
| Serum albumin pre-pro-protein | 4502027 | 69 | 986.0 | 332.8 | 2.4 | 0.00006 |
| Vitamin D-binding protein isoform 1 precursor | 32483410 | 53 | 51.9 | 19.2 | 2.4 | 0.03919 |
| Kininogen-1 isoform 2 precursor | 4504893 | 48 | 21.3 | 5.5 | 3.8 | 0.01109 |
| Alpha-2-macroglobulin precursor | 66932947 | 163 | 127.9 | 29.3 | 3.9 | 0.00618 |
| Haptoglobin isoform 1 pre-pro-protein | 4826762 | 45 | 83.8 | 18.0 | 4.2 | 0.00024 |
| Fibrinogen gamma chain isoform gamma-B precursor | 70906439 | 52 | 89.3 | 17.3 | 4.3 | 0.00133 |
| Complement C3 precursor | 115298678 | 187 | 174.7 | 35.6 | 4.3 | 0.00612 |
| Myeloperoxidase precursor | 4557759 | 84 | 70.2 | 11.0 | 5.3 | 0.02501 |
| Apolipoprotein A-I pre-pro-protein | 4557321 | 31 | 29.8 | 5.9 | 5.7 | 0.02170 |
| Fibrinogen alpha chain isoform alpha-E pre-pro-protein | 4503689 | 95 | 63.3 | 9.3 | 6.4 | 0.00031 |
| Alpha-2-HS-glycoprotein pre-pro-protein | 156523970 | 39 | 7.3 | 1.1 | 6.5 | 0.00173 |
| Ceruloplasmin precursor | 4557485 | 122 | 47.3 | 5.6 | 7.5 | 0.00114 |
| PREDICTED: complement C4-A isoform 1 | 341916194 | 193 | 32.1 | 4.5 | 7.7 | 0.01791 |
| Alpha-1B-glycoprotein precursor | 21071030 | 54 | 10.9 | 1.2 | 8.3 | 0.00468 |
| Inter-alpha-trypsin inhibitor heavy chain H4 isoform 1 precursor | 31542984 | 103 | 5.5 | 0.2 | 35.4 | 0.00484 |
| Apolipoprotein B-100 precursor | 105990532 | 516 | 49.3 | 1.0 | 55.7 | 0.02595 |
MW = molecular weight; SC = spectral count; NSAF = normalized spectral abundance factor